Managing advanced heart failure (HF) remains a major clinical challenge, especially for patients who no longer respond to conventional treatment options, or are not candidates for heart transplantation. In such cases, left ventricular assist devices (LVADs) have become an important option, offering mechanical support that has the potential to extend life and improve daily functioning. With ongoing advancements in technology, there is growing interest in understanding how LVADs impact not just survival, but also pa…

[This corrects the article DOI: 10.7759/cureus.88527.].

Abstract Enzyme replacement therapy (ERT) using velmanase alfa previously showed promising efficacy and safety outcomes for up to 4 years of therapy in patients with alpha‐mannosidosis. This pooled analysis from two multicenter, open‐label phase IIIb extension trials rhLAMAN‐07 ( N = 13; NCT01908712) and rhLAMAN‐09 ( N = 8; NCT01908725) evaluated the long‐term effects of velmanase alfa. Sixteen patients who previously completed phase I–III rhLAMAN‐02/‐03/‐04/‐05/‐08 trials and five ERT‐naïve patients were enrolled…

Background Patients with stage 4 CKD and type 2 diabetes have limited treatment options to reduce their persistent cardiovascular and kidney risk. In Finerenone in Chronic Kidney Disease and Type 2 Diabetes (FIDELITY), a prespecified pooled analysis of Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) and Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD), finerenone improved heart-kidney outcomes in participant…

Abstract Aims Finerenone reduces the risk of cardiovascular events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). We investigated the causes of mortality in the FIDELITY population. Methods and results The FIDELITY prespecified pooled data analysis from FIDELIO-DKD and FIGARO-DKD excluded patients with heart failure and reduced ejection fraction. Outcomes included intention-to-treat and prespecified on-treatment analyses of the risk of all-cause and cardiovascular mortality. Of 13 026 pat…